Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

313
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
313
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

9.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.4K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.1K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

477
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
477
Regulated Protein Degradation02:58

Regulated Protein Degradation

3.2K
3.2K
Regulated Protein Degradation02:58

Regulated Protein Degradation

9.0K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Forces behind N- and C-capping of peptidic helices.

Chemical communications (Cambridge, England)·2026
Same author

Cancer immunotherapeutic targeting tropomyosin receptor kinase C (TrkC) through its conjugate and cyclophosphamide.

Immunopharmacology and immunotoxicology·2025
Same author

Small-Molecule Trk Agonists: Where Do We Go from Here?

Journal of medicinal chemistry·2025
Same author

Selective Modulation of Trk Receptors by <i>Cyclo</i>-Organopeptides.

ACS chemical neuroscience·2025
Same author

Selective, Intrinsically Fluorescent Trk Modulating Probes.

ACS chemical neuroscience·2024
Same author

Bioinformatics leading to conveniently accessible, helix enforcing, bicyclic ASX motif mimics (BAMMs).

Nature communications·2024

Related Experiment Video

Updated: Feb 19, 2026

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

4.6K

PROTACs for Collateral Degradation: Is It Time to Back Up the Bus?

Zhe Gavin Gao1, Kevin Burgess1

  • 1Department of Chemistry, Texas A & M University, Box 30012, College Station, Texas 77842, United States.

ACS Medicinal Chemistry Letters
|February 18, 2026
PubMed
Summary

Off-target effects in drug development are typically avoided. However, for Proteolysis Targeting Chimeras (PROTACs) and other degraders, these effects can be beneficial when targeting protein complexes.

Keywords:
CDKHDACPBAFPRC2PROTACscell cyclecyclindegrader

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.2K

Related Experiment Videos

Last Updated: Feb 19, 2026

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

4.6K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.2K

Area of Science:

  • Drug development
  • Molecular biology
  • Biochemistry

Background:

  • Off-target effects are generally considered detrimental in pharmaceutical research and development.
  • The utility of off-target activities in drug design is an underexplored area.
  • Proteolysis Targeting Chimeras (PROTACs) and similar molecular degraders offer novel therapeutic modalities.

Purpose of the Study:

  • To investigate the potential advantages of off-target effects in drug development.
  • To explore scenarios where targeting multiprotein complexes, rather than single proteins, is therapeutically relevant.
  • To re-evaluate the role of off-target activities in the context of novel degraders like PROTACs.

Main Methods:

  • Literature review and theoretical analysis of drug-target interactions.
  • Case study analysis of existing PROTACs and molecular degraders.
  • Bioinformatic analysis of protein-protein interaction networks.

Main Results:

  • Off-target effects can be advantageous for PROTACs and degraders when the therapeutic goal involves modulating the function of multiprotein complexes.
  • The activity of a targeted protein may be less critical than the collective function of a protein complex in certain disease contexts.
  • Understanding complex-level interactions can guide the design of more effective degraders.

Conclusions:

  • The conventional view of off-target effects as solely undesirable needs revision, particularly for complex-targeting agents.
  • PROTACs and other degraders present opportunities to leverage off-target activities for therapeutic benefit.
  • Future drug development strategies should consider the modulation of multiprotein complexes through carefully designed off-target interactions.